These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 15301592

  • 1. Epidemiological characteristics of leprosy reactions: 15 years experience from north India.
    Kumar B, Dogra S, Kaur I.
    Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):125-33. PubMed ID: 15301592
    [Abstract] [Full Text] [Related]

  • 2. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M, Berhe D.
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
    [Abstract] [Full Text] [Related]

  • 3. Histoid leprosy: a retrospective study of 40 cases from India.
    Kaur I, Dogra S, De D, Saikia UN.
    Br J Dermatol; 2009 Feb; 160(2):305-10. PubMed ID: 19016704
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for erythema nodosum leprosum.
    Manandhar R, LeMaster JW, Roche PW.
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
    [Abstract] [Full Text] [Related]

  • 5. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India.
    Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, Lockwood DN.
    Am J Trop Med Hyg; 2006 May; 74(5):868-79. PubMed ID: 16687695
    [Abstract] [Full Text] [Related]

  • 6. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY, Wallach D, Spindler E, Pennec J, Cottenot F, Flageul B.
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [Abstract] [Full Text] [Related]

  • 7. Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospective study, comparing the experience of multibacillary patients receiving either 12 or 24 months WHO-MDT.
    Balagon M, Saunderson PR, Gelber RH.
    Lepr Rev; 2011 Sep; 82(3):213-21. PubMed ID: 22125929
    [Abstract] [Full Text] [Related]

  • 8. Reaction cases treated at the Regional Leprosy Training and Research Institute, Aska, Orissa: a retrospective analysis.
    Santaram V, Porichha D.
    Indian J Lepr; 2004 Sep; 76(4):310-20. PubMed ID: 16119141
    [Abstract] [Full Text] [Related]

  • 9. Incidence of late lepra reaction among multibacillary leprosy patients after MDT.
    Vijayakumaran P, Manimozhi N, Jesudasan K.
    Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714
    [Abstract] [Full Text] [Related]

  • 10. Some unusual type 2 reactions in leprosy.
    Ramesh V, Pahwa M.
    Int J Dermatol; 2010 Feb; 49(2):172-5. PubMed ID: 20465641
    [Abstract] [Full Text] [Related]

  • 11. Epidemiologic characteristics of leprosy reactions.
    Scollard DM, Smith T, Bhoopat L, Theetranont C, Rangdaeng S, Morens DM.
    Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):559-67. PubMed ID: 7868954
    [Abstract] [Full Text] [Related]

  • 12. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
    Feuth M, Brandsma JW, Faber WR, Bhattarai B, Feuth T, Anderson AM.
    Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
    [Abstract] [Full Text] [Related]

  • 13. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
    de Carsalade GY, Achirafi A, Flageul B.
    Acta Leprol; 2003 Sep; 12(3):117-22. PubMed ID: 15040702
    [Abstract] [Full Text] [Related]

  • 14. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
    Sampaio EP, Malta AM, Sarno EN, Kaplan G.
    Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
    [Abstract] [Full Text] [Related]

  • 15. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
    Kaur I, Dogra S, Kumar B, Radotra BD.
    Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
    [Abstract] [Full Text] [Related]

  • 16. Occurrence and management of leprosy reaction in China in 2005.
    Shen J, Liu M, Zhou M, Wengzhong L.
    Lepr Rev; 2009 Jun; 80(2):164-9. PubMed ID: 19743620
    [Abstract] [Full Text] [Related]

  • 17. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
    Narang T, Kaur I, Kumar B, Radotra BD, Dogra S.
    Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
    [Abstract] [Full Text] [Related]

  • 18. Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT + once a month Minocycline and Ofloxacin.
    Katoch K, Katoch VM, Natarajan M, Gupta UD, Sharma VD, Singh HB.
    Indian J Lepr; 2008 Jun; 80(4):331-44. PubMed ID: 20329382
    [Abstract] [Full Text] [Related]

  • 19. Unexplained delayed nerve impairment in leprosy after treatment.
    Rosenberg NR, Faber WR, Vermeulen M.
    Lepr Rev; 2003 Dec; 74(4):357-65. PubMed ID: 14750581
    [Abstract] [Full Text] [Related]

  • 20. Relapse of lepromatous leprosy after WHO/MDT with rapid bacterial growth.
    Oliveira ML, Pierro AP, Silveira PA, Campos MM, Vilela MF.
    Lepr Rev; 2002 Dec; 73(4):386-8. PubMed ID: 12549846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.